Advertisement
Advertisement

CTMX

CTMX logo

CytomX Therapeutics, Inc.

5.70
USD
Sponsored
-0.04
-0.78%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

5.65

-0.04
-0.79%

CTMX Earnings Reports

Positive Surprise Ratio

CTMX beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$8.06M
/
-$0.08
Implied change from Q3 25 (Revenue/ EPS)
+35.13%
/
-11.11%
Implied change from Q4 24 (Revenue/ EPS)
-78.85%
/
-134.78%

CytomX Therapeutics, Inc. earnings per share and revenue

On Nov 06, 2025, CTMX reported earnings of -0.09 USD per share (EPS) for Q3 25, missing the estimate of -0.05 USD, resulting in a -74.42% surprise. Revenue reached 5.96 million, compared to an expected 11.86 million, with a -49.71% difference. The market reacted with a -13.60% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 8.06 million USD, implying an decrease of -11.11% EPS, and increase of 35.13% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, CytomX Therapeutics, Inc. reported EPS of -$0.09, missing estimates by -74.42%, and revenue of $5.96M, -49.71% below expectations.
The stock price moved down -13.6%, changed from $4.19 before the earnings release to $3.62 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 10 analysts, CytomX Therapeutics, Inc. is expected to report EPS of -$0.08 and revenue of $8.06M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement